Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILENT TECHNOLOGIES, INC.A · Entity 3062 | Senior Vice President | May 08, 2026 | May 12, 2026 |
| BIO-RAD LABORATORIES, INC.BIO BIOB · Entity 2247 | EVP, President, LSG | March 08, 2024 | March 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILENT TECHNOLOGIES, INC.
Report date May 08, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,015.487 |
Reported balance
After 2026-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-08 · Tax withholding · Disposed 368 · Balance 14,015.487 F1: The reporting person surrendered 368 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. F2: Includes 3.457 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan in transactions exempt under Rule 16a-11. F3: Includes 172.7831 shares acquired in an Employee Stock Purchase Plan under Section 423 of the Internal Revenue Code of 1986, as amended, in a transaction exempt under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person surrendered 368 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3.
F2: Includes 3.457 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan in transactions exempt under Rule 16a-11.
F3: Includes 172.7831 shares acquired in an Employee Stock Purchase Plan under Section 423 of the Internal Revenue Code of 1986, as amended, in a transaction exempt under Rule 16b-3.
BIO-RAD LABORATORIES, INC.
Report date March 08, 2024 · Filed March 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $343.76 · Expires 2034-03-08 | Direct | 3,535 |
Reported balance
After 2024-03-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-08 · Grant · Acquired 3,535 · Balance 3,535 F1: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 12, 2026 20:11 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 368 | $115.62 | $42,548.16 |
DisclosureSEC source: 0001090872-26-000045 · form4.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,015.487 F1 · shares: The reporting person surrendered 368 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. F2 · balance_after: Includes 3.457 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan in transactions exempt under Rule 16a-11. F3 · balance_after: Includes 172.7831 shares acquired in an Employee Stock Purchase Plan under Section 423 of the Internal Revenue Code of 1986, as amended, in a transaction exempt under Rule 16b-3. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:31 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 300 | $154.37 | $46,311.00 |
DisclosureSEC source: 0001090872-25-000079 · form4.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,207.2469 F1 · shares: The reporting person surrendered 300 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 22:20 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 6,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001090872-25-000062 · form4.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,507.2469 F1 · price: Restricted Stock Units granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. The restricted stock units vest in four equal annual installments beginning on November 18, 2026. F2 · balance_after: Includes 234.83 shares acquired in an Employee Stock Purchase Plan under Section 423 of the Internal Revenue Code of 1986, as amended, in a transaction exempt under Rule 16b-3. Read SEC document |
| May 08, 2025 Filed May 9, 2025 21:03 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | Tax withholdingCommon Stock | 368 | $108.70 | $40,001.60 |
DisclosureSEC source: 0001127602-25-013874 · form4.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,491.4169 F1 · shares: The reporting person surrendered 368 shares to Agilent Technologies, Inc. to satisfy the tax liability on the vesting of restricted stock units in accordance with Rule 16b-3. F2 · balance_after: 172.4169 shares acquired in an Employee Stock Purchase Plan under Section 423 of the Internal Revenue Code of 1986, as amended, in a transaction exempt under Rule 16b-3. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 23:29 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,968 | $138.14 Strike: $138.14 | $1,376,979.52 |
DisclosureSEC source: 0000950170-24-132353 · ownership.xml · derivative · entry 2 MAY SIMON · CIK 0001900904 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,968 Underlying: Common Stock · 9,968 shares Expires 2034-11-27 F2 · security: Right to buy Agilent Technologies, Inc. common stock granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. F3 · derivative.exercise_date: The option is exercisable in four equal annual installments beginning on the first anniversary of the date of the grant. The first vesting date is stated. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 23:29 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 3,452 | $138.14 | $476,859.28 |
DisclosureSEC source: 0000950170-24-132353 · ownership.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,687 F1 · shares: Restricted Stock Units granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. The restricted stock units vest in four equal annual installments beginning on November 27, 2024 and are subject to a 1-year post-vest holding period. Read SEC document |
| May 08, 2024 Filed May 9, 2024 01:14 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,792 | $142.80 Strike: $142.80 | $1,683,897.60 |
DisclosureSEC source: 0001127602-24-014688 · form4.xml · derivative · entry 2 MAY SIMON · CIK 0001900904 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,792 Underlying: Common Stock · 11,792 shares Expires 2034-05-08 F2 · security: Right to buy Agilent Technologies, Inc. common stock granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. F3 · derivative.exercise_date: The option is exercisable in four equal annual installments beginning on the first anniversary of the date of the grant. The first vesting date is stated. Read SEC document |
| May 08, 2024 Filed May 9, 2024 01:14 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 4,235 | $142.80 | $604,758.00 |
DisclosureSEC source: 0001127602-24-014688 · form4.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,235 F1 · shares: Restricted Stock Units granted under the Agilent Technologies, Inc. 2018 Stock Plan, in compliance with Rule 16b-3. The restricted stock units vest in four equal annual installments beginning on May 8, 2025 and are subject to a 1 year post-vest holding period. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,535 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006220 · form4.xml · derivative · entry 1 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,535 Underlying: Bio-Rad A Common Stock · 3,535 shares Expires 2034-03-08 F1 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · derivative · entry 16 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F9 · derivative.exercise_date: On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F9 · derivative.expiration_date: On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 04, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 295 | $394.60 | $116,407.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 10 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,104.9894 Read SEC document |
| September 04, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 9 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,399.9894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 03, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 526 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · derivative · entry 15 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526 Underlying: Bio-Rad A Common Stock · 526 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: On September 3, 2019, the reporting person was granted 2,629 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F8 · derivative.expiration_date: On September 3, 2019, the reporting person was granted 2,629 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 03, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 182 | $394.60 | $71,817.20 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 8 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,799.9894 Read SEC document |
| September 03, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 526 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 7 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,981.9894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 409 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · derivative · entry 14 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410 Underlying: Bio-Rad A Common Stock · 409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 1,637 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 1,637 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 142 | $394.60 | $56,033.20 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 6 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,455.9894 Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 5 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,597.9894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 371 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · derivative · entry 13 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744 Underlying: Bio-Rad A Common Stock · 371 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 1,486 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 1,486 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 520 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · derivative · entry 12 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,562 Underlying: Bio-Rad A Common Stock · 520 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 2,082 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 2,082 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 3,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · derivative · entry 11 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,005 Underlying: Bio-Rad A Common Stock · 3,005 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 129 | $394.60 | $50,903.40 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 4 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,188.9894 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 371 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 3 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,317.9894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 180 | $394.60 | $71,028.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 2 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,946.9894 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 520 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,126.9894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 32.1340 and 24.5800 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2023 and 06/30/2023. Read SEC document |
| September 05, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · derivative · entry 12 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 5, 2017, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 5, 2017, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 05, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 298 | $478.32 | $142,539.36 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · nonDerivative · entry 8 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550.2754 Read SEC document |
| September 05, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · nonDerivative · entry 7 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,848.2754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · derivative · entry 11 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 04, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 285 | $478.32 | $136,321.20 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · nonDerivative · entry 6 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,248.2754 Read SEC document |
| September 04, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · nonDerivative · entry 5 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,533.2754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 526 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · derivative · entry 10 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052 Underlying: Bio-Rad A Common Stock · 526 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 3, 2019, the reporting person was granted 2,629 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 3, 2019, the reporting person was granted 2,629 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 182 | $478.32 | $87,054.24 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · nonDerivative · entry 4 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933.2754 Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 526 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · nonDerivative · entry 3 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,115.2754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 409 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · derivative · entry 9 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819 Underlying: Bio-Rad A Common Stock · 409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 1,637 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 1,637 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 142 | $478.32 | $67,921.44 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · nonDerivative · entry 2 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589.2754 Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:16 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019284 · form4.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731.2754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:58 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 371 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019196 · form4.xml · derivative · entry 4 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,115 Underlying: Bio-Rad A Common Stock · 371 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 1,486 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 1,486 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:58 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 2,082 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019196 · form4.xml · derivative · entry 3 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,082 Underlying: Bio-Rad A Common Stock · 2,082 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:58 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 129 | $486.25 | $62,726.25 |
DisclosureSEC source: 0001062993-22-019196 · form4.xml · nonDerivative · entry 2 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322.2754 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 17:58 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 371 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019196 · form4.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451.2754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 24.0465 and 12.8145 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2022 and 06/30/2022, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.